20年不懈对乙肝研究终于开花结果

YIGAN12

真的很感谢解除我们痛苦的人和第一个带给我们这个好消息的人！

朋友们坚持就是胜利！

建议：我们病好的那一天，所有的网友都要欢聚一堂，开一个大大大大大大大大的PARTY。

阿肝

两种分子结构的不同说明什麽？？？？？？下面的NV-02B和NV-02C是什麽意思？？？？试药期？？？？

特深沉

选自http://www.novirio.com/

----------------------------------------------------------------------------

We’re working to develop new antiviral treatments for chronic HBV infection. Alone and as components of

我们正在开发一种新的抗慢性HBV感染疗法。因其独特的化合物有效成分，该种新抗病毒

combination therapy regimens, these new antiviral drugs are targeted toward offering significantly improved

药物将目标定在为世界范围内的慢性HBV感染患者提供有显著改善的治疗疗效，体现在：

treatment for patients with chronic hepatitis B, worldwide, in the following respects:

Improved clinical effectiveness - more patients achieving durable treatment responses, and earlier in treatment

改善临床疗效——更多的患者将从治疗早期就获得可持久的疗效。

Good safety, with few or no side effects

安全性好——很少或没有副作用。

Convenient oral dosing – e.g., well-absorbed tablets to be taken once or twice daily

方便的口服量——比如，每日只需服一到两次易吸收的药片。

As improved treatment options become available, hepatitis B infection may be more effectively

当有更多可选的改良疗法时，我们可以混合两种或两种以上的有效药物来治疗HBV感染。

treated by combining two or more potent drugs. Consequently, we are developing a series of nucleoside antiviral

因此，我们正在开发一系列的核苷类抗病毒药，可以单独或联合应用治疗HBV。

drug candidates that may be used alone or in combination therapy for the treatment of HBV. Novirio’s first drug

Novirio的第一种抗HBV候选药物，被称为LdT,正在按美国新药调查程序（IND）进行

candidate for the treatment of HBV, which we refer to as LdT, is currently in a phase I/II clinical trial under a US 七期临床实验。

Investigational New Drug Application (IND). We have also received permission from the U.S. FDA to begin clinical  我们也从美国药物管理局（FDA）获得许可，对第二种抗HBV候选药物，LdC, 开始临床实验。          testing of a second HBV drug candidate, called LdC. In laboratory studies and predictive animal models of HBV

                                                                   在实验室研究中和前期的HBV动物样本中，

disease, LdT and LdC each demonstrated potent and highly specific antiviral activity against HBV; and in

LdT 和 LdC都表现出了有效和很明确的抗HBV活性；在合用两种药物时，甚至表现出

combination these two agents demonstrated even greater antiviral activity than either drug alone, a phenomenon

比单用任何一种药物都高的抗病毒活性，该现象称为抗病毒“协同”。

known as antiviral "synergy".

-----------------------------------------------------

-----------------------------------------------------------------------------------

LdT

A potent, selective and specific nucleoside antiviral

一种有选择性的，特效的核苷类抗病毒药。

Profound suppression of HBV-DNA after 4 weeks of treatment

经4周治疗后，可深度抑制HBV-DNA

Specifically inhibits hepatitis B virus

特异性地抑制HBV病毒。

Once daily oral administration

每日一次口服。

Currently in phase I/II clinical trial in HBV-infected individuals

正在个别HBV感染者中进行七期临床实验。

DEVELOPMENT STATUS: phase I/II human clinical trial ongoing

开发状态：对人的七期临床实验进行中。

----------------------------------------------------------------------------------------------

LdC

A potent, selective and specific nucleoside antiviral, synergistic with LdT

一种有选择性的，特效的核苷类抗病毒药，可增强 LdT效果。

Potency in animal models is superior to lamivudine and most other investigational drugs

在动物实验中，疗效超过拉米夫定或大多数其他研发中的药物

Specifically inhibits hepatitis B virus

特异性地抑制HBV病毒。

Highly synergistic with LdT in vitro and in animal models

在动物实验中，可大大增强 LdT效果。

Once daily oral administration

每日一次口服。

Currently in phase I/II clinical trial in HBV-infected individuals

正在个别HBV感染者中进行七期临床实验。

DEVELOPMENT STATUS: phase I/II human clinical trial ongoing

开发状态：对人的七期临床实验进行中。



We are developing two additional HBV nucleoside drug candidates,

which we refer to as NV-02A and NV-06.

我们正在开发另外两种抗HBV核苷类候选药物，我们称为NV-02A 和 NV-06。

Further pre-clinical evaluation will be required on these potential drug candidates.

这些潜在的候选 药物需进行更多的临床评估。

森非尔

谢谢liver411和特深沉。

[ 此消息由 森非尔 在 2002-01-02.19:48:13 编辑过 ]

lll

我们的春天不远了！

红樱枪

这确是个好消息， 不过看了研究报告，还是老一套，还是抑制，



看来终生服药，还是免不了，这种药我们穷人是吃不起的。



希望国内的医药工业快点发展起来。

linx

对于乙肝的彻底治疗看来还不是短期内的事，但五年内大概可以有数种药物供我们选择以提供有效的病毒抑制，阻断疾病的进展。

毛毛

引用:

---

原文由 眼镜 发表: 世界卫生组织说要在2015年前攻克乙肝

---

这个消息那儿的来的？我要去翻翻报纸了。

medline

谢谢liver411 兄 总是给我们大家提供很好的消息.

论坛上懂英文的朋友有空请多去英文论坛

(HBV English,里面liver411版主经常转贴一些他精选出来的乙肝方面的国外的好文章.)看看. 参与讨论

方便的话,翻译一些好文章到中文论坛上来.

大家一起出力,能使论坛更好.



------------------------------------------------



谢谢liver411 兄 在新年的第一天提供了这么好的消息.

和 谢谢特深沉 的翻译.



这种抗病毒药 原理类似拉米夫丁.而且安全性好. 作用效果好.



我们的未来充满希望.





下面是一篇国外科学杂志的报道的文摘.

2001;12月 的抗病毒化学药物杂志发表

作者就是开发这家药物的公司.



大意是， 这种药（LdC,LdT,LdA）能够特异的（表现在不抑制其他15种别的病毒的复制）抑制乙肝病毒的复制，不影响人体DNA的正常复制。在旱獭慢性乙肝动物模型中，每天一次口服能够有效的降低病毒滴度到10的8次放。 并能相应的降低表面抗原。这一类药表现出极好的安全性。其中一种LdT已经进入临床试验。

LdC即将进入临床试验。

这类药物的组合使用将会达到很强的抑制病毒以及缩小耐药性的产生。



------------------------------------------

Antivir Chem Chemother 2001;12 Suppl 1:119-29



Antiviral beta-L-nucleosides specific for hepatitis B virus infection.



Novirio Pharmaceuticals, Cambridge, Mass, USA. [email protected]



[Medline record in process]





Three simple, related nucleosides, beta-L-2'-deoxycytidine (LdC), beta-Lthymidine (LdT), and beta-L-2'-deoxyadenosine (LdA), have been discovered to be potent, specific and selective inhibitors of the replication hepatitis B virus (HBV), as well as the closely related duck and woodchuck hepatitis viruses (WHV). Structure-activity relationship analysis indicates that the 3'-OH group of the beta-L-2'-deoxyribose of the beta-L-2'-deoxynucleoside confers specific anti-hepadnavirus activity. The simple nucleosides had no effect on the replication of 15 other RNA and DNA viruses, and did not inhibit human DNA polymerases (alpha, beta and gamma) or compromise mitochondrial function. The nucleosides are efficiently converted intracellularly into active triphosphate metabolites that have a long half-life. Once-daily oral administration of these compounds in the woodchuck efficacy model of chronic HBV infection reduced viral load by as much as 10(8) genome equivalents/ml serum and there was no drug-related toxicity. In addition, a decline in WHV surface antigen (WHsAg) paralleled the decrease in viral load. This class of nucleosides displays an excellent overall safety profile. The first compound, LdT, has already entered clinical trials and LdC, currently being developed as a prodrug, is expected to enter the clinic in the near future. These compounds have the potential for use in combination therapy with the goal of achieving superior viral suppression and diminishing the onset of resistance.

混元灵通

明天会更好!!!